Partner News

NS Pharma Partnership with Capricor Therapeutics

In 2015, CureDuchenne supplied early funding to Capricor Therapeutics in support of a novel, first-in-class therapy to improve cardiac function in people with Duchenne muscular dystrophy. Duchenne can cause debilitating […]

Clinical Hold of DYNE-251

On January 14th 2022, the U.S. FDA placed a clinical hold on Dyne’s Investigational New Drug (IND) submission for the launch of their clinical trial of DYNE-251, which targets Duchenne […]

Sarepta News Banner

Sarepta Announces Results From SRP-9001 Study

Sarepta today announced topline results from Part 2 of Study 102, an ongoing, randomized, double-blind, placebo-controlled clinical trial evaluating its investigational gene transfer therapy SRP-9001 in Duchenne patients.   In […]